HC Wainwright Issues Negative Forecast for FULC Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at HC Wainwright decreased their Q1 2025 earnings estimates for Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.27) per share for the quarter, down from their prior estimate of ($0.22). HC Wainwright has a "Neutral" rating and a $4.00 price objective on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics' Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.16) EPS, FY2026 earnings at ($1.36) EPS, FY2027 earnings at ($1.35) EPS and FY2028 earnings at ($1.15) EPS.

Separately, Royal Bank of Canada reiterated a "sector perform" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Fulcrum Therapeutics currently has an average rating of "Hold" and a consensus price target of $8.63.

Fulcrum Therapeutics Price Performance

NASDAQ FULC traded up $0.03 during mid-day trading on Friday, hitting $3.27. The stock had a trading volume of 401,900 shares, compared to its average volume of 467,435. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70. The firm's 50 day moving average is $4.08 and its 200 day moving average is $4.46. The stock has a market capitalization of $176.51 million, a price-to-earnings ratio of -10.55 and a beta of 2.03.

Remove Ads

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Suvretta Capital Management LLC grew its stake in shares of Fulcrum Therapeutics by 182.3% in the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock valued at $15,691,000 after buying an additional 2,155,675 shares during the period. Braidwell LP purchased a new position in Fulcrum Therapeutics in the third quarter worth approximately $3,817,000. Adage Capital Partners GP L.L.C. increased its stake in Fulcrum Therapeutics by 50.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company's stock worth $14,100,000 after acquiring an additional 1,000,000 shares during the last quarter. Woodline Partners LP raised its position in Fulcrum Therapeutics by 110.3% in the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock valued at $6,629,000 after purchasing an additional 739,713 shares during the period. Finally, State Street Corp grew its holdings in shares of Fulcrum Therapeutics by 61.4% during the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company's stock worth $5,998,000 after purchasing an additional 638,955 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.